Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: FOLFOX chemotherapy is widely used as an adjuvant treatment for advanced colon cancer. The duration of adjuvant chemotherapy is usually set to 6 months, which is based on a former study of 5-fluorouracil/leucovorin chemotherapy. However, the FOLFOX regimen is known to have complications, such as peripheral neuropathy. The aim of this study was to compare the survival rates and complications experienced by patients receiving either 4 or 6 months of FOLFOX chemotherapy.
Methods: Retrospective data analysis was performed for stage II and III patients who underwent radical resection of colon cancer. We compared the 5-year survival rates and the occurrence of complications in patients who completed only 8 cycles of FOLFOX chemotherapy with patients who completed 12 cycles of chemotherapy.
Results: Among 188 patients who underwent adjuvant FOLFOX chemotherapy for stage II or III colon cancer, 83 (44.1%) completed 6 months of FOLFOX chemotherapy and 64 (34.0%) patients discontinued after 4 months of chemotherapy. The 5-year overall survival and disease-free survival rates did not show a significant difference. Patients in the 6-month group had peripheral neuropathy more frequently (p = 0.028).
Conclusions: Five-year overall and disease-free survival were not significantly different between the 2 groups. Large-scale prospective studies are necessary for the analysis of complications and survival rates.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000481566 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Natural product Erianin: mitigating FOLFOX toxicity and enhancing against colorectal cancer.
Front Chem
August 2025
Guangzhou Key Laboratory of Formula-Pattern Research Center, School of Traditional Chinese Medicine, The Fifth Affiliated Hospital of Jinan University (Heyuan Shenhe People's Hospital), Jinan University, Guangzhou, China.
Introduction: Colorectal cancer (CRC) is a prevalent malignant tumor of the digestive tract. The FOLFOX regimen (oxaliplatin + calcium folinate + 5-fluorouracil) serves as the primary treatment for advanced CRC clinically, yet its application is significantly limited by substantial toxic side effects. Erianin, a natural compound from Chinese medicine Lindl, demonstrates significant potential in both tumor growth inhibition and chemotherapy toxicity reduction.
View Article and Find Full Text PDFTotal tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trial.
Eur J Cancer
August 2025
Department of Surgery, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands; Cancer Center, Amsterdam, the Netherlands.
Introduction: This study aimed to assess whether total tumor volume (TTV) outperforms RECIST1.1 for treatment response assessment in patients with colorectal liver metastases (CRLM), and to investigate TTV as a predictive biomarker for the optimal systemic treatment regimen for individual patients with initially unresectable CRLM.
Methods: Patients with initially unresectable liver-only CRLM from the phase 3 CAIRO5 trial (NCT02162563) were included.
Comparison of second-line chemotherapy regimens in advanced biliary tract cancer: a systematic review, meta-analysis, and population-based cohort study.
Int J Surg
September 2025
Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Background: Biliary tract cancers (BTCs) are aggressive malignancies with limited treatment options, especially after first-line chemotherapy failure. FOLFIRINOX, though established for pancreatic cancer, has shown promise in advanced BTC, yet its role as a second-line treatment remains unclear. To address this gap, we conducted a retrospective cohort study to evaluate the efficacy and safety of FOLFIRINOX and performed a systematic review with meta-analysis to compare its outcomes with currently recommended regimens, including FOLFIRI, FOLFOX, and nal-IRI/FL.
View Article and Find Full Text PDFUnresectable Primary Enteric-Type Thymic Adenocarcinoma Treated With FOLFOX Chemotherapy: A Case Report.
Cancer Rep (Hoboken)
September 2025
Department of Oncology, Eastern Health, Melbourne, Australia.
Background: Enteric-type thymic adenocarcinomas are an extremely rare and distinct subtype of thymic malignancies, as classified by the 2021 World Health Organization classification of thymic tumors. These tumors exhibit close molecular and morphologic similarity to primary gastrointestinal malignancies. To date, there are no tailored treatment guidelines for enteric-type thymic adenocarcinoma.
View Article and Find Full Text PDFComparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study.
Ther Adv Med Oncol
August 2025
Department of Medical Oncology, Mehmet Akif İnan Research and Training Hospital, Şanlıurfa, Turkey.
Background: Metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) cancer are associated with a poor prognosis. Recent advancements in treatment have incorporated trastuzumab, anti-PD-1 agents, and anti-claudin therapies alongside chemotherapy (ChT), significantly improving outcomes. Contemporary studies predominantly employ doublet ChT as the backbone for these regimens, although historically triplet ChT regimens have been favored, particularly in younger patients requiring rapid tumor shrinkage.
View Article and Find Full Text PDF